PH12014500785A1 - Method for treating capillary hemangiomas - Google Patents
Method for treating capillary hemangiomasInfo
- Publication number
- PH12014500785A1 PH12014500785A1 PH1/2014/500785A PH12014500785A PH12014500785A1 PH 12014500785 A1 PH12014500785 A1 PH 12014500785A1 PH 12014500785 A PH12014500785 A PH 12014500785A PH 12014500785 A1 PH12014500785 A1 PH 12014500785A1
- Authority
- PH
- Philippines
- Prior art keywords
- capillary hemangiomas
- treating capillary
- treating
- hemangiomas
- human
- Prior art date
Links
- 208000001969 capillary hemangioma Diseases 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 abstract 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 abstract 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Otolaryngology (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Electromagnetism (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548838P | 2011-10-19 | 2011-10-19 | |
| PCT/IB2012/002509 WO2013057580A1 (en) | 2011-10-19 | 2012-10-15 | Method for treating capillary hemangiomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014500785A1 true PH12014500785A1 (en) | 2014-05-12 |
Family
ID=47630411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2014/500785A PH12014500785A1 (en) | 2011-10-19 | 2012-10-15 | Method for treating capillary hemangiomas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150044148A1 (enExample) |
| EP (1) | EP2768501A1 (enExample) |
| JP (1) | JP2014530847A (enExample) |
| KR (1) | KR20140091544A (enExample) |
| CN (1) | CN103889416A (enExample) |
| AU (1) | AU2012324544B2 (enExample) |
| BR (1) | BR112014009209A2 (enExample) |
| CA (1) | CA2850277A1 (enExample) |
| IL (1) | IL231821A0 (enExample) |
| MX (1) | MX2014004386A (enExample) |
| PH (1) | PH12014500785A1 (enExample) |
| RU (1) | RU2014119919A (enExample) |
| WO (1) | WO2013057580A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| TWI709417B (zh) | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| CN105764496B (zh) | 2013-10-07 | 2020-09-25 | 帝国制药美国公司 | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 |
| EP4138803A1 (en) * | 2020-04-21 | 2023-03-01 | Université catholique de Louvain | Alpha-2 adrenergic receptor agonists for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| CN1108565A (zh) * | 1994-10-21 | 1995-09-20 | 孙强 | 百草滴鼻液及其制备方法 |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| CN1391901A (zh) * | 2001-06-18 | 2003-01-22 | 赵培玲 | 治疗血管瘤的注射剂 |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| US8633181B2 (en) * | 2009-04-09 | 2014-01-21 | Rutgers, The State University Of New Jersey | Treatment of cutaneous hemangioma |
| CN101962404A (zh) * | 2010-06-17 | 2011-02-02 | 中国热带农业科学院热带生物技术研究所 | 一种用于治疗血管瘤的蛋白质 |
-
2012
- 2012-10-15 CA CA2850277A patent/CA2850277A1/en not_active Abandoned
- 2012-10-15 US US14/344,091 patent/US20150044148A1/en not_active Abandoned
- 2012-10-15 JP JP2014536350A patent/JP2014530847A/ja active Pending
- 2012-10-15 RU RU2014119919/15A patent/RU2014119919A/ru not_active Application Discontinuation
- 2012-10-15 KR KR1020147011913A patent/KR20140091544A/ko not_active Withdrawn
- 2012-10-15 AU AU2012324544A patent/AU2012324544B2/en not_active Ceased
- 2012-10-15 BR BR112014009209A patent/BR112014009209A2/pt not_active IP Right Cessation
- 2012-10-15 CN CN201280051518.7A patent/CN103889416A/zh active Pending
- 2012-10-15 PH PH1/2014/500785A patent/PH12014500785A1/en unknown
- 2012-10-15 EP EP12820881.6A patent/EP2768501A1/en not_active Withdrawn
- 2012-10-15 MX MX2014004386A patent/MX2014004386A/es unknown
- 2012-10-15 WO PCT/IB2012/002509 patent/WO2013057580A1/en not_active Ceased
-
2014
- 2014-03-31 IL IL231821A patent/IL231821A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140091544A (ko) | 2014-07-21 |
| BR112014009209A2 (pt) | 2017-04-18 |
| JP2014530847A (ja) | 2014-11-20 |
| CA2850277A1 (en) | 2013-04-25 |
| WO2013057580A1 (en) | 2013-04-25 |
| IL231821A0 (en) | 2014-05-28 |
| AU2012324544B2 (en) | 2016-11-24 |
| RU2014119919A (ru) | 2015-11-27 |
| EP2768501A1 (en) | 2014-08-27 |
| US20150044148A1 (en) | 2015-02-12 |
| AU2012324544A1 (en) | 2014-05-01 |
| CN103889416A (zh) | 2014-06-25 |
| MX2014004386A (es) | 2014-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390843A1 (ru) | Применение агониста toll-подобного рецептора для лечения рака | |
| MX383365B (es) | Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
| GB201114051D0 (en) | Compounds and their uses | |
| EA201390948A1 (ru) | Лечение боли, обусловленной смещением базального слоя эндометрия | |
| MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| MX2010000724A (es) | Metodo para reducir presion intracraneal. | |
| IN2014CN04634A (enExample) | ||
| MX356933B (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| MX349854B (es) | Composiciones antitranspirantes y metodo para reducir la transpiracion. | |
| IT1406864B1 (it) | Composizione per il trattamento dell'acne | |
| PH12014500785A1 (en) | Method for treating capillary hemangiomas | |
| MY175326A (en) | Product and method for treating diarrhea | |
| MX2013010050A (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
| MX2015012580A (es) | El uso de sdf-1 para atenuar la formacion de cicatrices. | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| UA113859C2 (xx) | Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| EA201690445A1 (ru) | Лечение рака | |
| PH12014500783A1 (en) | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |